CAJ | 학술논문

目的分析瑞舒伐他汀治疗对高血压伴2型糖尿病患者平均血小板体积的影响.方法选取高血压伴2型糖尿病患者共186名,在常规降压、降糖治疗的基础上随机分为饮食运动干预组(A组,治疗后为)、瑞舒伐他汀10mg qd干预组(B组)、瑞舒伐他汀20mg qd干预组(C组)治疗.随访1个月,测量各组干预前后的身高、体重、血压、血糖、糖化血红蛋白、血脂、血小板计数、平均血小板体积、谷丙转氨酶、血肌酐和肌酶学.结果治疗前后各组别之间的身高、体重、血压、血糖、糖化血红蛋白、血小板计数、谷丙转氨酶、血肌酐和肌酶学没有统计学差异.A、B、C组之间治疗后血脂变化具有统计学差异:TG(3.32±1.23 vs 2.24±1.23 vs 2.13±1.04mmol/L,P<0.05),TC(5.16±1.47 vs 3.30±1.20 vs 3.01±1.08 mmol/L,P<0.05),LDL-C(2.92±1.43 vs 2.07±1.32 vs 1.94±1.21 mmol/L,P<0.05), HDL-C(0.93±0.24 vs 1.08±0.30 vs 1.12±0.32 mmol/L,P<0.05).A、B、C组之间的平均血小板体积变化治疗后具有统计学差异:(9.87±1.52 vs 8.17±1.33 vs 7.63±1.18fl,P<0.05).结论瑞舒伐他汀可以有效调节高血压伴2型糖尿病患者的血脂异常,在调脂治疗之外瑞舒伐他汀可有效安全地降低该类患者的平均血小板体积.
목적분석서서벌타정치료대고혈압반2형당뇨병환자평균혈소판체적적영향.방법선취고혈압반2형당뇨병환자공186명,재상규강압、강당치료적기출상수궤분위음식운동간예조(A조,치료후위)、서서벌타정10mg qd간예조(B조)、서서벌타정20mg qd간예조(C조)치료.수방1개월,측량각조간예전후적신고、체중、혈압、혈당、당화혈홍단백、혈지、혈소판계수、평균혈소판체적、곡병전안매、혈기항화기매학.결과치료전후각조별지간적신고、체중、혈압、혈당、당화혈홍단백、혈소판계수、곡병전안매、혈기항화기매학몰유통계학차이.A、B、C조지간치료후혈지변화구유통계학차이:TG(3.32±1.23 vs 2.24±1.23 vs 2.13±1.04mmol/L,P<0.05),TC(5.16±1.47 vs 3.30±1.20 vs 3.01±1.08 mmol/L,P<0.05),LDL-C(2.92±1.43 vs 2.07±1.32 vs 1.94±1.21 mmol/L,P<0.05), HDL-C(0.93±0.24 vs 1.08±0.30 vs 1.12±0.32 mmol/L,P<0.05).A、B、C조지간적평균혈소판체적변화치료후구유통계학차이:(9.87±1.52 vs 8.17±1.33 vs 7.63±1.18fl,P<0.05).결론서서벌타정가이유효조절고혈압반2형당뇨병환자적혈지이상,재조지치료지외서서벌타정가유효안전지강저해류환자적평균혈소판체적.
Objective To investigate the effect of rosuvastatin on mean platelet volume in patients with essential hypertension complicated with type 2 diabetes mellitus. Methods:one huntred and eighty-six patients with essential hypertension complicated with type 2 diabetes mellitus were recruited. All patients undertaken routine antihypertensive and antidiabetic therapy were randomly divided into three groups, recived diet and exercise intervension(group A), rosuvastatin 10mg/d(group B) and rosuvastatin 20mg/d(group C) for a month respectively. The height, weight, blood pressure, blood glucose, glycated hemoglobin, lipids, platelet count, mean platelet volume, alanine aminotransferase, serum creatinine and creatase were detected before and after intervension. Results:The distinctions of height, weight, blood pressure, blood glucose, glycated hemoglobin, platelet count, alanine aminotransferase, serum creatinine and creatase had not been statistically significant among the three groups after therapy. The distinctions of lipids had been statistically significant among group A, group B and group C after therapy[TG(3.32±1.23 vs 2.24±1.23 vs 2.13±1.04mmol/L, P<0.05), TC(5.16±1.47 vs 3.30±1.20 vs 3.01±1.08 mmol/L, P<0.05), LDL-C(2.92±1.43 vs 2.07±1.32 vs 1.94±1.21 mmol/L, P<0.05), HDL-C(0.93±0.24 vs 1.08±0.30 vs 1.12±0.32 mmol/L, P<0.05)].The distinction of mean platelet volume had been statistically significant among group A, group B and group C after therapy(9.87±1.52 vs 8.17±1.33 vs 7.63±1.18fl, P<0.05). Conclusion:Rosuvastatin could improve the dyslipidemia in patients with essential hypertension complicated with type 2 diabetes mellitus, and in addition to this, it could also decrease their mean platelet volume efficiently and safely.